Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbons Patents (Class 514/188)
-
Patent number: 8828984Abstract: Provided herein is a method of synthesis of Au(III)-NHC complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Au(III)-NHC complexes. Also provided is method of detecting thiol in a biological system. The Au(III)-NHC complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.Type: GrantFiled: November 13, 2013Date of Patent: September 9, 2014Assignee: The University of Hong KongInventors: Chi Ming Che, Taotao Zou
-
Patent number: 8829028Abstract: This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic heart disease. Methods of treating heart failure using 5-HT4 receptor antagonists and pharmaceutical compositions containing 5-HT4 receptor antagonists are also provided.Type: GrantFiled: February 17, 2009Date of Patent: September 9, 2014Assignee: Serodus ASInventor: Finn Olav Levy
-
Publication number: 20140248342Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use in the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.Type: ApplicationFiled: May 30, 2012Publication date: September 4, 2014Applicant: Vifor (International) AGInventors: Thomas Bark, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Camillo Canclini, Franz Dürrenberger, Felix Funk, Peter Geisser, Aris Kalogerakis, Simona Mayer, Erik Philipp, Stefan Reim, Diana Sieber, Jörg Schmitt, Katrin Schwarz, Jürgen Klotz
-
Publication number: 20140243301Abstract: A method of manufacturing an anhydrous copper complex of formula C12H10CICuN2O4 and methods of treating neur-muscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, Alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (GP), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention.Type: ApplicationFiled: August 9, 2012Publication date: August 28, 2014Applicant: C Lab Pharma International S.A.Inventors: Sean Kerrigan, Nolan Mente, Charles Louis Albartus Barker
-
Patent number: 8796252Abstract: The present invention is directed to a stable, soluble, antimicrobial composition concentrate comprising pyrithione or a pyrithione complex in an amount of from about 0.5% to about 30 weight percent, a zinc source in an amount of from about 0.1% to about 10%, and an organic amine component in an amount of from about 30% to about 80%, said percents being based upon the total weight of the composition concentrate. The invention is also directed to methods of controlling the growth of free-living microorganisms or biofilms using the antimicrobial composition of the invention, and products made using the antimicrobial composition of the invention.Type: GrantFiled: December 23, 2004Date of Patent: August 5, 2014Assignee: Arch Chemicals, Inc.Inventors: Michelle L. Rioux, Diana T. Ciccognani, Thomas J. Palys, Patricia A. Turley
-
Publication number: 20140212497Abstract: The present invention relates to a method for preparing a composition comprising nanoparticles of a noble metal functionalised with at least one type of metal complex and surfactant. The method comprises providing a first solution comprising nanoparticles and surfactant, and a second solution comprising a first type of metal complex, and adding the second solution to the first solution. Each nanoparticle has a loading of at least 500 and the method permits independent control of particle size and loading and enables large particles with high loading to be reproduced without agglomeration.Type: ApplicationFiled: June 28, 2012Publication date: July 31, 2014Inventors: Zoe Pikramenou, Nicola Rogers
-
Publication number: 20140186466Abstract: Disclosed are compositions of matter useful for the treatment of diabetes. In one embodiment a nutraceutical composition is administered to a patient in need, said composition comprising of one or more ingredients selected from a group consisting of: magnesium, chromium picolinate, alpha lipoic acid, Garcina indica, holy basil, Morodica charantica, cinnamon, Salacia reticulate, Salacia oblonga, Gymnema sylvestre, nopal cactus, fenu greek, vanadium, 1-carnitine, and vitamin D3.Type: ApplicationFiled: December 31, 2013Publication date: July 3, 2014Applicant: Creative Medical Health Inc.Inventor: Amit Patel
-
Publication number: 20140186278Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.Type: ApplicationFiled: September 19, 2013Publication date: July 3, 2014Inventor: Patrick Franke
-
Publication number: 20140154189Abstract: The present invention, therefore, is directed to an antimicrobial compositions that decreases the bioavailability of iron by introducing a higher-affinity iron-selective chelating agent capable of competing with microbial siderophores. In one aspect, the present invention relates to an antimicrobial composition including a potentiating antimicrobial composition including one or more antimicrobial agents and a chelator having a weight ratio of the antimicrobial agent to the chelator from about 1:1000 to about 1000:1.Type: ApplicationFiled: October 14, 2013Publication date: June 5, 2014Applicant: Arch Chemicals, Inc.Inventors: George Polson, Jody Jourden, Qi Zheng, Regina M. Prioli, Diana Ciccognani, Sungmee Choi
-
Publication number: 20140155368Abstract: Methods and combination pharmaceuticals for treating bronchospastic medical conditions by utilizing the electrophysiology of proteinacious channels in lipid membranes of mammalian cells. The combination pharmaceuticals include at least one ?-adrenergic receptor agonist, and at least one composition adapted to effect the electrophysiology of Kv7 potassium channels of a lipid membrane of an airway smooth muscle cell. The pharmaceutical may be administered to a living body in a therapeutic amount sufficient to activate the Kv7 potassium channels of an airway smooth muscle cell.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: Loyola University ChicagoInventor: Kenneth L. Byron
-
Publication number: 20140148425Abstract: Photosensitive compounds for use in a method of treating a disease or condition are described. The photosensitive compounds have the formula R—Y, wherein R is a ruthenium complex and Y is at least one sulphur-containing photoreleasable group, and the compounds comprise at least one ruthenium-sulphur bond; or a pharmaceutically acceptable salt, solvate, ester or amide, such that upon influence of visible or near infra-red light (400-1400 nm) in vivo, said at least one ruthenium-sulphur bond is broken, thereby generating a pharmacologically active compound.Type: ApplicationFiled: October 18, 2011Publication date: May 29, 2014Inventor: Sylvestre Bonnet
-
Publication number: 20140142080Abstract: Provided herein is a method of synthesis of Au(III)-NHC complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Au(III)-NHC complexes. Also provided is method of detecting thiol in a biological system. The Au(III)-NHC complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.Type: ApplicationFiled: November 13, 2013Publication date: May 22, 2014Applicant: University of Hong KongInventors: Chi Ming CHE, Taotao ZOU
-
Publication number: 20140121165Abstract: The present invention relates to process for identifying a compound which induces the mitochondrial permeability transition (MPT) in proliferating cells, wherein said process comprises contacting a cell or cell extract with a compound, determining whether the compound binds to adenine nucleotide translocator (ANT), and determining whether the compound selectively induces the MPT in proliferating cells.Type: ApplicationFiled: October 25, 2013Publication date: May 1, 2014Applicant: NewSouth Innovations Pty LimitedInventor: Philip John Hogg
-
Publication number: 20140113005Abstract: The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.Type: ApplicationFiled: January 16, 2013Publication date: April 24, 2014Applicant: Vertex Pharmaceuticals IncorporatedInventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8703756Abstract: A method of reducing the in vivo viability of cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells has steps of: a) identifying a prospective patient having cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells; and b) administering a cisplatin derivative to the prospective patient so that the cisplatin derivative will contact the cancer cells; wherein the cisplatin derivative is a 4,4?-bis[RO]-2,2?-bipyridine)PtCl2 where, R is selected from the group consisting of —(CH2)nCH3 where n=2, 3, 4 or 5, and —(CH2)n[O(CH2)m]yO(CH2)zCH3 where n=2, m=2, y=2, z=1. A novel synthetic process for the manufacture of these compounds (and their analogs) is also provided.Type: GrantFiled: February 24, 2012Date of Patent: April 22, 2014Assignee: The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada, Las VegasInventors: Bryan L. Spangelo, Van Vo, Pradip K. Bhowmik, Ontida Tanthmanatham, Haesook Han
-
Patent number: 8697041Abstract: A shampoo composition is described which includes from 1 to 25% by weight of mild surfactants, from 0.001 to 5% by weight of citrus fibers, from 0.01 to 5% by weight of anti-dandruff zinc salts, and a cosmetically acceptable carrier. The citrus fibers help structure the composition to maintain phase stability, provide appropriate viscosity and achieve deposition of the anti-dandruff zinc salts.Type: GrantFiled: August 10, 2010Date of Patent: April 15, 2014Assignee: Conopco, Inc.Inventors: Yury Yarovoy, Georgia Shafer, Albert Joseph Post
-
Patent number: 8691726Abstract: A synergistic antimicrobial composition containing a glyphosate compound and zinc pyrithione is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition.Type: GrantFiled: December 9, 2011Date of Patent: April 8, 2014Assignee: Dow Global Technologies LLCInventors: Emerentiana Sianawati, Sudhakar Balijepalli
-
Publication number: 20140093517Abstract: Methods for diagnosing and treating conditions associated with life-threatening neurological complications are provided. The methods involve in some aspects the identification of oxLDL and LOX-1 as critical players in pregnant subjects and in some cases subjects having severe preeclampsia (early onset preeclampsia). Related products and kits are also provided.Type: ApplicationFiled: October 3, 2013Publication date: April 3, 2014Inventor: Marilyn J. Cipolla
-
Publication number: 20140066419Abstract: The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Yu Chen, Yi Chen
-
Publication number: 20140057887Abstract: Disclosed are novel platinum-carbene complexes and use thereof as medicinal products.Type: ApplicationFiled: December 22, 2011Publication date: February 27, 2014Inventors: Stéphane Bellemin-Laponnaz, Gilles Guichard, Edith Chardon
-
Publication number: 20140050793Abstract: The present invention includes a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention also includes the method of preparing a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention further includes a method of causing virolysis of a virus using the compositions described therein.Type: ApplicationFiled: October 5, 2011Publication date: February 20, 2014Applicant: Drexel UniversityInventors: Irwin Chaiken, Arangassery Rosemary Bastian, Kantharaju
-
Publication number: 20140045970Abstract: A synergistic antimicrobial composition containing 3-iodo-2-propynyl-butylcarbamate and fluometuron.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Inventors: Emerentiana Sianawati, Sangeeta Ganguly
-
Publication number: 20140038933Abstract: The present invention provides a composition containing a pyrithione compound and a pyranone compound and a method of reducing discoloration of compositions containing pyrithione compounds. The composition may be a soap composition.Type: ApplicationFiled: July 30, 2013Publication date: February 6, 2014Applicant: Arch Chemicals, Inc.Inventors: George Polson, Jody Jourden, Denise B. Taylor, Yongcheng Ji
-
Patent number: 8633174Abstract: Pharmaceutical compositions comprise a first compound of Formula I or a physiologically acceptable salt thereof, and a cyto-protective amount of a manganese chelate of N,N?-dipyridoxyl ethylenediamine-N,N?-diacetic acid (MnPLED): wherein R1, R2, R3, R4 and X are defined in the specification.Type: GrantFiled: February 16, 2013Date of Patent: January 21, 2014Assignee: PledPharma ABInventors: Jan Olof G Karlsson, Tino Kurz, Rolf Andersson
-
Patent number: 8623826Abstract: Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.Type: GrantFiled: March 31, 2011Date of Patent: January 7, 2014Assignee: Helsinn Healthcare S.A.Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
-
Publication number: 20130345189Abstract: A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.Type: ApplicationFiled: June 13, 2013Publication date: December 26, 2013Inventors: Jacqueline K. Barton, Alexis Komor, Curtis J. Schneider, Alyson Weidmann, Russell Ernst
-
Publication number: 20130344166Abstract: A topical mixture intended to reduce undesirable Iron levels in the cells to optimize Mitochondrial functioning. A method of reducing undesirable levels of Iron in the cells to optimize Mitochondrial functioning.Type: ApplicationFiled: June 25, 2012Publication date: December 26, 2013Inventor: PIERRE ERNEST LOUBET
-
Patent number: 8592405Abstract: A synergistic antimicrobial composition containing 3-iodo-2-propynyl-butylcarbamate and fluometuron.Type: GrantFiled: July 28, 2010Date of Patent: November 26, 2013Assignee: Dow Global Technologies LLCInventors: Emerentiana Sianawati, Sangeeta S. Ganguly
-
Publication number: 20130309320Abstract: The present invention relates to combinations of 4-bromo-2-(4-chloro-phenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, and copper or zinc compounds which provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to compositions comprising a combination of 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, together with one or more copper or zinc compounds selected from Cu2O, Cu(OH)2, CuSO4, copper pyrithione, CuSCN, CuCO3, ZnO, ZnCl2, ZnSO4, zineb, and zinc pyrithione; in respective proportions to provide a synergistic effect against fouling organisms and the use of these compositions for protecting materials against fouling organisms. This invention thus relates to the field of protection of materials, such as underwater objects, protection of wood, wood products, biodegradable materials and coatings.Type: ApplicationFiled: July 24, 2013Publication date: November 21, 2013Applicant: Janssen Pharmaceutica, NVInventor: Tony Mathilde Jozef Kempen
-
Publication number: 20130303503Abstract: The present invention relates to a personal cleansing composition with an antimicrobial effect. The personal cleansing composition is in the form of a bar soap and contains zinc pyrithione and a soap surfactant. When dispersed in an aqueous solution at 1 wt %, the personal cleansing composition of the present invention is characterized by a pH value ranging that is higher than about 9.6 and lower than about 10.3. The present invention also relates to a process for forming an antimicrobial bar soap as described hereinabove.Type: ApplicationFiled: May 9, 2013Publication date: November 14, 2013Applicant: The Procter & Gamble CompanyInventors: Edward Dewey SMITH, III, Jason Edward COOK, Chunpeng JIANG, Ian David HENRY, Juan WANG, Casey Patrick KELLY, Xiujun XU, Zhe LIU
-
Publication number: 20130296289Abstract: The invention relates to an anti-dandruff shampoo comprising: —a) from 0.1 to 5 wt. % of an anti-dandruff zinc salt; b) from 1 to 8 wt. % of a branched alkyloyi isethionate; c) from 1 to 10 wt. % of a fatty acyl isethionate product which product comprises 40 to 80 wt. % fatty acyl isethionate and 15 to 50 wt. % free fatty acid and/or fatty acid salt; and, d) from 0.5 to 14 wt. % of a co-surfactant; and to the use of the branched alkyloyi isethionate to improve the deposition of an anti-dandruff zinc salt onto the scalp.Type: ApplicationFiled: November 17, 2011Publication date: November 7, 2013Inventors: Caroline Alexandra Hall, Graham Andrew Turner, Aneliya Nikolova Zdravkova
-
Publication number: 20130289011Abstract: To provide an aqueous antibacterial dispersion which contains a metal pyrithione salt and a cationic polymer and which can maintain a stable dispersed state. An antibacterial dispersion characterized by containing at least one cationic polymer, at least one metal pyrithione salt, and at least one non-anionic surfactant. In an aqueous dispersion of the metal pyrithione salt, the non-anionic surfactant is blended instead of a conventional anionic component, whereby good dispersion stability can be maintained in a cationic polymer blend system.Type: ApplicationFiled: August 11, 2011Publication date: October 31, 2013Applicant: API CorporationInventor: Masaaki Yoshimaru
-
Publication number: 20130289005Abstract: A kit for treatment of acne vulgaris, said formulation of the kit effectively inhibiting or killing Proprionibacterium without antibiotics. A preferred formulation alleviates the four pathogenic factors of acne. In a preferred method using the kit, a first skin-wash formulation comprising a higher zinc pyrithione concentration than the second leave-on formulation is applied to the affected area and subsequently washed off the skin with water. Then, a second leave-on formulation, preferably comprising a minimum of 0.25% zinc pyrithione with additional ingredients for eliminating or reducing other pathogenic factors of acne vulgaris, is applied to the skin. The kit includes a skin-wash component and a leave-on component comprising the acne treatment of the invention. Formulations are preferably applied as creams, lotions or emulsions.Type: ApplicationFiled: October 23, 2012Publication date: October 31, 2013Inventor: B. Eugene Guthery
-
Publication number: 20130287833Abstract: Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided.Type: ApplicationFiled: June 21, 2013Publication date: October 31, 2013Inventors: Thierry Glauser, Stephen D. Pacetti, Paul M. Consigny
-
Publication number: 20130273183Abstract: 2-Pyrimidine thioesters and thiocarbonates are disclosed as effective skin brightening agents. These compounds may be formulated with dermatologically acceptable carriers to form skin brightening compositions. Methods for brightening skin and for inhibiting melanogenesis using these agents are also disclosed.Type: ApplicationFiled: April 13, 2012Publication date: October 17, 2013Applicant: EASTMAN CHEMICAL COMPANYInventors: Stephanie Kay Clendennen, Liu Deng, Neil Warren Boaz
-
Publication number: 20130267483Abstract: This invention relates to complexes of certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including molybdenum, having a hydroxy acid [HA] and an amino acid [AA] moiety concurrently bound to a single said metal and having a spirocyclic, bidentate chelate structure of formula (I). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation.Type: ApplicationFiled: February 6, 2013Publication date: October 10, 2013Applicant: BIODERM RESEARCHInventor: SHYAM K GUPTA
-
Publication number: 20130252933Abstract: A cleansing composition comprising at least 5% of a surfactant, at least about 25% water, a cyclodextrin complex comprising a perfume, wherein 80% of the plurality of perfume raw materials comprise a FDV of at least 0.69.Type: ApplicationFiled: March 23, 2012Publication date: September 26, 2013Inventors: Timothy Alan SCAVONE, Jianjun Justin Li, Marc Adam Flickinger, Jonathan Robert Cetti
-
Patent number: 8530659Abstract: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.Type: GrantFiled: October 27, 2010Date of Patent: September 10, 2013Assignee: The University of Hong KongInventors: Chi Ming Che, Raymond Wai-Yin Sun, Lok Fung Chow, Jing Yan
-
Patent number: 8524214Abstract: Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.Type: GrantFiled: May 27, 2010Date of Patent: September 3, 2013Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Gui Liu, Laura C. Akullian, John J. Kane, Cheri A. Stevenson, Charles E. Hammond, Russell C. Petter, John H. Van Duzer, Timothy B. Lowinger
-
Publication number: 20130225546Abstract: A method of reducing the in vivo viability of cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells has steps of: a) identifying a prospective patient having cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells; and b) administering a cisplatin derivative to the prospective patient so that the cisplatin derivative will contact the cancer cells; wherein the cisplatin derivative is a 4,4?-bis[RO]-2,2?-bipyridine)PtCl2 where, R is selected from the group consisting of —(CH2)nCH3 where n=2, 3, 4 or 5, and —(CH2)n[O(CH2)m]yO(CH2)zCH3 where n=2, m=2, y=2, z=1. A novel synthetic process for the manufacture of these compounds (and their analogs) is also provided.Type: ApplicationFiled: February 24, 2012Publication date: August 29, 2013Applicants: NevedaInventors: Bryan L. Spangelo, Van Vo, Pradip K. Bhowmik, Ontida Tanthmanatham, Haesook Han
-
Publication number: 20130225547Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.Type: ApplicationFiled: April 29, 2013Publication date: August 29, 2013Applicant: Yeda Research and Development Co., Ltd.Inventor: Yeda Research and Development Co. Ltd.
-
Publication number: 20130224258Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.Type: ApplicationFiled: February 12, 2013Publication date: August 29, 2013Applicant: MICROBION CORPORATIONInventor: Microbion Corporation
-
Patent number: 8518934Abstract: The invention relates to oxycarbamoyl compounds of Formula I: The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.Type: GrantFiled: June 11, 2009Date of Patent: August 27, 2013Assignee: Shonogi & Co., Ltd.Inventor: Hidenori Mikamiyama
-
Publication number: 20130209823Abstract: The present invention provides a method of protecting wood or other celiulosic material from decay by copper-tolerant fungi, and wood preservative formulations for use in the same. The wood preservative formulations comprise a biocidal metal compound, a 1,2,4-triazole and a didecyl quaternary ammonium cation. Didecyldimethyl quaternary ammonium compounds are particularly preferred.Type: ApplicationFiled: June 21, 2011Publication date: August 15, 2013Applicant: ARCH TIMBER PROTECTION LIMITEDInventors: Craig Andrew Mars, David Grindon Cantrell, Kevin Hughes, Andrew Stewart Hughes
-
Publication number: 20130210793Abstract: The present invention provides compounds of Formula I: along with compositions comprising the same and methods of using the same, such as for photodynamic therapy in the treatment of cancer.Type: ApplicationFiled: March 21, 2013Publication date: August 15, 2013Applicant: Duke UniversityInventor: Duke University
-
Patent number: 8506990Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.Type: GrantFiled: October 10, 2012Date of Patent: August 13, 2013Inventor: Lawrence Richard Bernstein
-
Publication number: 20130203725Abstract: A method for treatment of small cell lung cancer (SCLC) that does not respond to first-line treatment or that progresses following cessation of first-line organoplatinum chemotherapy is provided that includes the administration of picoplatin, optionally in conjunction with a regimen of best supportive care. Multiple doses of picoplatin can be administered. The picoplatin can also treat SCLC that has metastacized to the brain.Type: ApplicationFiled: March 4, 2011Publication date: August 8, 2013Applicant: Poniard Pharmaceuticals, Inc.Inventors: Hazel B. Breitz, Robert De Jager, Paul L. Weiden
-
Publication number: 20130202690Abstract: The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant.Type: ApplicationFiled: September 27, 2012Publication date: August 8, 2013Applicant: Poniard Pharmaceuticals, Inc.Inventors: Alistair J. Leigh, Christopher A. Procyshyn, Angelica F. Phillips, Hazel B. Breitz
-
Patent number: 8501725Abstract: A synergistic antimicrobial composition containing flumetsulam or diclosulam; and zinc pyrithione.Type: GrantFiled: November 4, 2011Date of Patent: August 6, 2013Assignee: Dow Global Technologies LLCInventor: Emerentiana Sianawati
-
Patent number: RE44704Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.Type: GrantFiled: September 13, 2012Date of Patent: January 14, 2014Assignee: Immunogen Inc.Inventors: Ravi V. J. Chari, Walter A. Blättler